These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21792009)

  • 1. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
    Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
    Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
    Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
    Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells.
    Li X; Wang X; Yang Y; Xu C; Shen H
    Oncol Rep; 2012 Jul; 28(1):248-54. PubMed ID: 22469813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
    Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
    Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
    Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
    Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
    Yoshida K; Hamai Y; Suzuki T; Sanada Y; Oue N; Yasui W
    Anticancer Res; 2006; 26(1A):49-54. PubMed ID: 16475678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
    Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
    Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
    Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
    Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?
    Keller JA; Erson-Bensan AE; Petty EM
    Cancer Biol Ther; 2010 Nov; 10(9):942-4. PubMed ID: 21057211
    [No Abstract]   [Full Text] [Related]  

  • 10. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
    Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
    Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
    Privette LM; González ME; Ding L; Kleer CG; Petty EM
    Cancer Res; 2007 Jul; 67(13):6064-74. PubMed ID: 17596595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
    Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
    Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
    Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
    Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways.
    Li Z; Min W; Gou J
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1001-11. PubMed ID: 24036847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
    Zhang X; Feng Y; Wang XY; Zhang YN; Yuan CN; Zhang SF; Shen YM; Fu YF; Zhou CY; Li X; Cheng XD; Lu WG; Xie X
    Cell Death Dis; 2018 Jan; 9(2):93. PubMed ID: 29367628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
    Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
    Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
    Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
    Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.